The global arbidol tablets market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Arbidol tablets are the antiviral medications used for the treatment of the influenza virus along with coronavirus (COVID-19). The major factor attributing to the growth of the global arbidol tablets market is the increasing cases of COVID-19 across the globe. According to the statistics published by the World Health Organization (WHO), around 483 million cases of COVID-19 are confirmed including the mortality of around 6.13 million people till the end of March 2022.
In addition, the use of arbidol tablets in the treatment of symptoms of influenza virus is also increasing. According to the Centers for Disease Control and Prevention (CDC), around 8% of the total population of the US gets affected by the influenza virus every season causing several symptoms including fever, cough, sore throat, headaches, fatigue, and many others. Thus, increasing the demand for arbidol tablets. Furthermore, several developments in arbidol tablets are further contributing to the growth of the market. For instance, in June 2020, the Drug Controller General of India (DGCI) authorized the Council of Scientific and Industrial Research (CSIR) for the clinical trial for favipiravir and umifenovir (arbidol) for the treatment of COVID-19.
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, the Central Drug Research Institute (CDRI) announced that Umifenovir (Arbidol) is successful in the treatment of COVID-19 by reducing several symptoms including cough, tiredness, fever, difficulty in breathing, and chest pain, among others.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Arbidol Tablets Market at: https://orionmarketreports.com/request-sample/?id=104017&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Pharmasyntez, Jiangsu Simcere Pharmaceutical Co. Ltd., CSPC Pharmaceutical Group Ltd., Novartis International AG, and Teva Pharmaceuticals Industries Ltd., among others.
A full report Arbidol Tablets Market of is available at: https://orionmarketreports.com/arbidol-tablets-market/104017/
Global Arbidol Tablets Market Report by Segment
By Application
- Coronavirus
- Influenza Virus
- Other Respiratory Tract Diseases
By Distribution Channel
- Hospital Pharmacies
- Retail Drug Stores
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
